Sector News

Novartis in no rush to sell down stake on GSK consumer venture

July 20, 2016
Life sciences

Novartis is happy with the performance of its consumer health joint venture with GlaxoSmithKline, in which the Swiss drugmaker has a minority stake, and is in no rush to exit the collaboration early, its chief executive said.

There has been speculation that Novartis might look to try and sell its 36.5 percent holding before an agreed trigger date of 2018, but Joe Jimenez played down the idea in a post-results call with analysts on Tuesday.

He noted the consumer business was doing well, with profit margins now improving, suggesting a bright outlook for the business.

“There’s a put (option) in 2018 but as long as there’s value that’s going to continue to be generated here, we are happy to participate in it,” Jimenez said.

Some analysts have suggested that Novartis could use funds from selling its stake to help pay for any acquisitions, including in the hot area of cancer immunotherapy. Jimenez, however, said he did not feel any pressure to do deals in the immunotherapy field as Novartis had a promising early-stage pipeline of immune system-boosting medicines.

On the broader M&A front, Jimenez reiterated that Novartis had the flexibility to see its credit rating move down for the right deal, although he said the current focus was on smaller bolt-on acquisitions.

By Ben Hirschler

Source: Reuters

comments closed

Related News

December 3, 2023

FDA names chief scientist Bumpus as Woodcock’s successor

Life sciences

The Food and Drug Administration’s top scientist Namandjé Bumpus will assume the role of principal deputy commissioner when longtime agency leader Janet Woodcock retires from that role in early 2024, according to an announcement Thursday.

December 3, 2023

AbbVie to buy cancer drug maker ImmunoGen for $10.1 Billion

Life sciences

US biopharma AbbVie has agreed to acquire ImmunoGen in a deal which values the company at about $10.1 billion and gives AbbVie access to flagship cancer therapy Elahere (mirvetuximab soravtansine-gynx), a first-in-class antibody-drug conjugate (ADC) approved for platinum-resistant ovarian cancer (PROC), as well as a pipeline of promising next-generation ADCs.

December 3, 2023

EuroAPI appoints new Executive Committee members

Life sciences

EUROAPI today announced the appointment of David Seignolle as Chief Operating Officer, succeeding Eric Berger, and Marion Santin as Chief Legal, Compliance, and IP Officer, both joining the company’s Executive Committee. In his new role, David Seignolle will lead the transformation of the Industrial Operations organization.

How can we help you?

We're easy to reach